Adrian W Quartel sold $40k of ZVRA
Chief Medical Officer at ZEVRA THERAPEUTICS, INC.. 4,533 shares at an average of $8.83, traded Jan 30, 2026, filed Feb 2, 2026.
Score components
- +15RoleOfficer
- +6Trade size$40k at market
- +10Share of holdings soldSold 32% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -4.6%, 3m +7.4%, 6m +7.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001910132-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 30, 2026 | MOption exercise Common Stock10b5-1 | +11,333 | - | - | 14,256 | Feb 2, 2026 |
| Jan 30, 2026 | SOpen-market sale Common Stock10b5-1 | -4,533 | $8.83 | $40k | 9,723 | Feb 2, 2026 |
| Jan 29, 2026 | AGrant or award Restricted Stock Unitderivative10b5-1 | +37,500 | $0.00 | $0 | 37,500 | Feb 2, 2026 |
| Jan 29, 2026 | AGrant or award Stock Option (right to buy)derivative10b5-1 | +75,000 | $0.00 | $0 | 75,000 | Feb 2, 2026 |
| Jan 30, 2026 | MOption exercise Restricted Stock Unitderivative10b5-1 | -11,333 | $0.00 | $0 | 22,667 | Feb 2, 2026 |
Related signals
Other insiders at ZEVRA THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | ZEVRA THERAPEUTICS, INC. | Rahsaan Thompson Chief Legal & Compliance | $475k 42,666 shares | -53% | |
| 39Weak | ZEVRA THERAPEUTICS, INC. | Corey Michael Watton director | $138k 12,300 shares | -87% | |
| 7Weak | ZEVRA THERAPEUTICS, INC. | Rahsaan Thompson Chief Legal & Compliance | $438k 34,557 shares | -30% | |
| 0Weak | ZEVRA THERAPEUTICS, INC. | Rahsaan Thompson Chief Legal & Compliance | $20k 1,794 shares | -4% | |
| 16Weak | ZEVRA THERAPEUTICS, INC. | Neil F. McFarlane President and CEO | $125k 14,625 shares | -4% | |
| 15Weak | ZEVRA THERAPEUTICS, INC. | Timothy J. Sangiovanni SVP, Finance & Corp Controller | $28k 3,000 shares | -9% | |
| 25Weak | ZEVRA THERAPEUTICS, INC. | Joshua Schafer CCO | $97k 10,500 shares | -14% | |
| 33Weak | ZEVRA THERAPEUTICS, INC. | Neil F. McFarlane President and CEO | $853k 91,000 shares | -20% | |
| 0Weak | ZEVRA THERAPEUTICS, INC. | Timothy J. Sangiovanni SVP, Finance & Corp Controller | $15k 1,750 shares | -8% | |
| 0Weak | ZEVRA THERAPEUTICS, INC. | Joshua Schafer CCO | $30k 3,375 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.